CD137 (4-1BB; TNFRSF9) is an activating receptor binding to CD137L (4-1BBL; TNFSF9). Because CD137 is expressed on both natural killer (NK) cells and T cells, it can trigger both innate and adaptive immunity. After these cells have been activated by exposure to tumour antigen, CD137 signals stimulate them to reproduce and generate antitumour activity. CD137 has been shown to play a critical role on T cells in the development of immune memory and the creation of a durable immune response. On lymphocytes, the presence of CD137 appears to be a marker for tumour reactivity. Activation of CD137 signalling can stimulate both cytotoxic T cell and NK cell activity.
LIT: 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy: D.S. Vinay & B.S. Kwon; BMB Rep. 47, 122 (2014) • CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses: B. Dharmadhikari, et al.; Oncoimmunology 5, e1113367 (2015)
Biologically Active CD137 and CD137L Proteins
See all Biologically Active CD137 and CD137L Proteins by AdipoGen Life Sciences here.
See all Biologically Active CD137 and CD137L Proteins by Chimerigen here.
See all Biologically Active CD137 and CD137L Proteins by Ancell here.
VALIDATED Antibodies for CD137 and CD137L Research
See all VALIDATED Antibodies for CD137 and CD137L Research by AdipoGen Life Sciences here.
See all VALIDATED Antibodies for CD137 and CD137L Research by Ancell here.
Originally posted on adipogen.com/cd137-cd137l-pathway/
Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.